Skip to content

Amylyx Pharmaceuticals

US · AMLX #2392 by market cap Listed 2022
26.02 -0.18 -0.69%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Quant vs Street three independent views, side by side

StockVane factor grade
C+
Momentum strategy signal
Hold
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 9 analysts

Buy
Avg price target 46.25 +77.7%
Price target rangecurrent 26.02
Low39.00
Avg46.25
High57.00
Buy 100% Hold 0% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-10 Mizuho Securities -- Buy 39.00
2026-11-05 Citi -- Buy 39.00
2026-11-05 H.C. Wainwright -- Buy 55.00
2026-10-29 Mizuho Securities -- Buy 38.00
2026-10-16 Citi -- Buy 39.00
2026-10-15 Citi -- Buy 39.00
2026-10-01 Stifel -- Buy 45.00
2026-08-26 Guggenheim -- Buy 57.00
2026-08-22 LifeSci Capital -- Buy 44.00
2026-08-20 H.C. Wainwright -- Buy 55.00
2026-08-19 Mizuho Securities -- Buy 42.00
2026-08-19 H.C. Wainwright -- Buy 55.00
2026-08-18 TD Cowen -- Buy --
2026-08-18 LifeSci Capital -- Buy 44.00
2026-08-18 Mizuho Securities -- Buy 42.00
2026-08-18 BofA Securities -- Buy 39.00
2026-08-18 Baird -- Buy 52.00
2026-08-18 Stifel -- Buy --
2026-08-18 Citi -- Buy 32.00
2026-08-18 Guggenheim -- Buy 55.00
2026-08-18 H.C. Wainwright -- Buy 55.00
2026-08-17 Mizuho Securities -- Buy 30.00
2026-08-07 Baird -- Buy 28.00
2026-08-07 H.C. Wainwright -- Buy 34.00
2026-08-06 TD Cowen -- Buy --

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-05 -- ±10.38% -6.05% (in line)
2026/Q2 2026-08-06 -- ±29.34% +10.71% (in line)
2026/Q1 2026-05-07 -- ±9.74% -5.35% (in line)
2025/Q4 2026-03-03 -- ±19.28% -7.78% (in line)
2025/Q3 2025-11-06 -- ±18.20% -5.89% (in line)
2025/Q2 2025-08-07 -- ±18.78% -4.27% (in line)
2025/Q1 2025-05-08 -- ±26.63% -5.95% (in line)
2024/Q4 2025-03-04 -- ±21.67% +0.33% (in line)
2024/Q3 2024-11-07 -- ±17.35% +5.14% (in line)
2024/Q2 2024-08-08 -- ±24.20% -4.26% (in line)
2024/Q1 2024-05-09 -- ±15.03% -2.07% (in line)
2023/Q4 2024-02-22 -- ±24.55% +21.10% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Amylyx Pharmaceuticals discussion 0 comments

Add a comment